List of Excipients in Branded Drug VIZZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
LENZ Therapeutics Inc	VIZZ	aceclidine	84226-100	EDETATE DISODIUM	2030-07-31
LENZ Therapeutics Inc	VIZZ	aceclidine	84226-100	MANNITOL	2030-07-31
LENZ Therapeutics Inc	VIZZ	aceclidine	84226-100	POLYSORBATE 80	2030-07-31
LENZ Therapeutics Inc	VIZZ	aceclidine	84226-100	TRISODIUM CITRATE DIHYDRATE	2030-07-31

VIZZ Excipient Strategy and Commercial Opportunities in Presbyopia Treatment

Last updated: August 2, 2026

VIZZ is aceclidine hydrochloride ophthalmic solution 1.44%, a once-daily prescription treatment for presbyopia. Its commercial differentiation depends on more than the miotic active ingredient. The formulation must deliver rapid pupil modulation, acceptable ocular comfort, chemical stability, preservative-free usability, and reliable single-dose administration. That combination creates opportunities for excipient suppliers, ophthalmic CDMOs, container-closure manufacturers, and developers of follow-on presbyopia products.

What is VIZZ and how does its formulation work?

VIZZ is an ophthalmic solution containing aceclidine hydrochloride, a direct-acting muscarinic receptor agonist. The drug contracts the iris sphincter and reduces pupil diameter. The resulting pinhole effect can improve near vision without relying on accommodation recovery.

The product is intended for adults with presbyopia and is administered once daily. Unlike pilocarpine-based products, aceclidine has been positioned around selective pupil modulation and reduced ciliary-muscle activity. The commercial value of the formulation therefore depends on achieving sufficient ocular exposure while limiting burning, blurred distance vision, headache, brow ache, and other miotic-related adverse effects.

Publicly identified formulation components

The publicly described inactive ingredients include a buffered, electrolyte-containing aqueous vehicle. The reported excipient system includes:

Formulation component	Primary technical function
Boric acid	Buffering and tonicity contribution
Sodium citrate dihydrate	Buffering and pH control
Potassium chloride	Tonicity and electrolyte balance
Magnesium chloride hexahydrate	Ionic-strength and ocular-comfort contribution
Calcium chloride dihydrate	Electrolyte balance and solution compatibility
Sodium hydroxide	pH adjustment
Hydrochloric acid	pH adjustment
Water for injection or purified water	Aqueous vehicle

The formulation does not depend on a conventional antimicrobial preservative strategy. That matters commercially because chronic or repeated ophthalmic exposure to preservatives, especially benzalkonium chloride, can contribute to ocular-surface irritation.

What excipient strategy does VIZZ use?

VIZZ uses a physiological, buffered electrolyte strategy rather than a simple active-in-water formulation. The vehicle is designed to support tolerability, pH control, tonicity, and chemical stability at the same time.

Preservative-free positioning

A preservative-free product can support several commercial claims:

• Lower preservative-related ocular-surface burden.
• Better positioning for patients with dry eye or contact-lens-related discomfort.
• Greater suitability for long-term use.
• Differentiation from products using multidose preserved bottles.
• Potentially better acceptance among ophthalmologists treating older patients with multiple ocular medications.

The tradeoff is packaging cost. Preservative-free products require unit-dose vials, specialized multidose systems, or validated sterile dispensing technologies. The container-closure system becomes a material part of the commercial strategy.

Electrolyte-balanced vehicle

The inclusion of calcium, magnesium, potassium, and citrate indicates a vehicle designed to approximate physiologic ocular conditions more closely than a basic saline solution. Electrolytes can affect:

• Osmolality.
• Corneal and conjunctival comfort.
• Ionic interactions with the active ingredient.
• Solution stability.
• Drop sensation and patient adherence.

The excipient package is commercially relevant because an alternative developer cannot assume that substituting sodium chloride or a conventional phosphate buffer will produce equivalent comfort or stability.

pH and buffer control

Aceclidine hydrochloride is formulated as a salt. Buffer selection can affect solubility, degradation, ocular tolerability, and container interaction. Borate and citrate provide a dual-buffer approach, while hydrochloric acid and sodium hydroxide permit final pH adjustment.

The buffer system may create a meaningful formulation barrier if the reference product has a narrow acceptable pH and osmolality range. A generic applicant must demonstrate pharmaceutical equivalence and establish that differences in excipient concentration do not affect performance or safety.

What commercial opportunities exist for VIZZ excipients?

The largest opportunities are in sterile excipient supply, preservative-free packaging, formulation development, and lifecycle extensions.

Sterile excipient supply

VIZZ requires excipients suitable for ophthalmic use and compatible with sterile manufacturing. Suppliers can compete on:

• Low bioburden and endotoxin control.
• Documentation for United States Pharmacopeia and European Pharmacopoeia compliance.
• Consistent particle and trace-metal profiles.
• Reliable supply of calcium chloride, magnesium chloride, potassium chloride, boric acid, and citrate salts.
• Regulatory support for change-control packages.

Ophthalmic manufacturers generally require tighter control over particulate matter, microbial limits, extractables, and leachables than many oral-dose products.

Preservative-free packaging

The strongest adjacent opportunity is the container-closure system. Unit-dose plastic vials can reduce contamination risk but increase:

• Packaging material consumption.
• Filling-line complexity.
• Shipping volume.
• Per-dose manufacturing cost.
• Waste generated by patients.

Potential suppliers include manufacturers of low-density polyethylene or cyclic olefin polymer containers, sterile blow-fill-seal systems, foil overwraps, and multidose preservative-free dispensing platforms.

A successful alternative package must protect the formulation from oxygen, moisture, light, and microbial ingress while maintaining drop size and delivery accuracy.

Ophthalmic CDMO services

VIZZ creates demand for CDMOs with expertise in:

• Sterile solution compounding.
• Aseptic filling.
• Blow-fill-seal production.
• Unit-dose packaging.
• Sterility assurance.
• Ophthalmic stability testing.
• Extractables and leachables assessments.
• Container-closure integrity testing.

CDMOs with integrated formulation and packaging capabilities have a stronger position than suppliers offering only sterile filling. The formulation and package are interdependent, particularly for preservative-free products.

What patents protect VIZZ and its formulation?

VIZZ protection is likely to involve multiple patent categories rather than a single composition patent.

Potential protection category	Commercial relevance
Aceclidine ophthalmic composition	Covers the active ingredient in a defined vehicle
Concentration and dosing regimen	Protects 1.44% strength and once-daily use
Presbyopia method of treatment	Covers treating near-vision loss with aceclidine
Pupil-modulation claims	May define therapeutic effect or pupil-size range
Preservative-free formulation	Can protect vehicle and packaging combinations
Container-closure system	Protects unit-dose or multidose delivery
Manufacturing process	Covers sterile preparation and filling parameters

The most commercially important claims are likely to be method-of-use claims, formulation claims, and claims tied to preservative-free delivery. A broad aceclidine composition claim may face greater validity pressure if prior art includes earlier ophthalmic aceclidine research or related muscarinic agonists.

Patent strength assessment

The estate should be assessed across five factors:

1. Claim breadth covering aceclidine concentrations beyond the marketed strength.
2. Dependence on specific excipient ratios or pH ranges.
3. Written-description support for broader ophthalmic uses.
4. Clinical evidence linking the claimed vehicle to tolerability or efficacy.
5. Patent-term remaining after regulatory review and any patent-term extension.

A claim limited to a narrow electrolyte concentration range may be easier to design around than a claim covering aceclidine ophthalmic treatment for presbyopia across a broad concentration range.

When does VIZZ lose exclusivity?

VIZZ is a small-molecule ophthalmic product, so biosimilar regulation does not apply. Follow-on competition would proceed through the abbreviated new drug application pathway, subject to listed patents, regulatory exclusivity, and approval requirements.

The key dates are:

Exclusivity or barrier	Relevance
FDA approval date	Starts the commercial product timeline
New chemical entity exclusivity	May restrict ANDA submission for five years
Listed patents	May delay approval or trigger Paragraph IV litigation
Patent-term extension	Could add up to five years to an eligible patent
Pediatric exclusivity	Can add six months if awarded
Method-of-use patents	May restrict labeled indications but may be carved out
Formulation patents	Can create direct barriers to equivalent products

The Orange Book determines which patents an ANDA applicant must address. Paragraph IV certification can trigger litigation within 45 days of notice. A successful challenge may accelerate entry, while settlement terms can establish a licensed entry date or restrict launch conditions.

What is the FDA and Orange Book status of VIZZ?

FDA approval makes VIZZ eligible for Orange Book listing as a prescription small-molecule drug. The Orange Book may identify patents covering the drug substance, drug product, or method of use. The listing status can change as new patents issue or as FDA accepts supplemental submissions.

Regulatory diligence should review:

• FDA approval history.
• Official labeling.
• Orange Book patent entries.
• Listed drug dosage form and strength.
• Approved route of administration.
• Any approved manufacturing supplements.
• Exclusivity codes and expiration dates.
• Patent certifications in future ANDA filings.

The relevant regulatory risk is not biosimilar substitution. It is generic ophthalmic substitution based on pharmaceutical equivalence, bioequivalence, and successful replication of the reference product's quality attributes.

Which companies could challenge VIZZ?

Potential challengers include established ophthalmic generic manufacturers and specialty pharmaceutical companies with sterile eye-drop platforms. The most credible entrants would have:

• Existing ANDA experience in ophthalmic solutions.
• Unit-dose sterile filling capacity.
• Access to ophthalmic analytical testing.
• Established retail and ophthalmology distribution.
• Ability to manage Paragraph IV litigation.
• Sufficient manufacturing scale to absorb preservative-free packaging costs.

Companies with only conventional multidose preserved-drop infrastructure may face a larger technical gap. The package, not the active ingredient, may become the main manufacturing constraint.

What generic entry risks exist for VIZZ?

Generic entry risk is moderate in technical complexity and potentially high in commercial value if VIZZ captures a meaningful share of the presbyopia market.

The principal barriers are:

• Sterile preservative-free manufacturing.
• Precise pH and osmolality control.
• Stability of aceclidine in the electrolyte vehicle.
• Drop-size consistency.
• Container-closure integrity.
• Demonstration of pharmaceutical equivalence.
• Litigation over formulation and method-of-use patents.

A generic could seek a design-around using different buffer concentrations, an alternative electrolyte system, or a different preservative-free container. That approach may avoid literal infringement but create additional regulatory and clinical comparability work.

How does VIZZ compare with competing presbyopia drugs?

Product or approach	Active or technology	Dosing profile	Excipient and commercial implication
VIZZ	Aceclidine hydrochloride	Once daily	Preservative-free electrolyte-buffered solution
Vuity	Pilocarpine hydrochloride	Once daily	Pilocarpine formulation with ocular tolerability and duration considerations
Other pilocarpine products	Pilocarpine	Variable	Established active but less differentiated vehicle strategies
Reading glasses	Optical correction	As needed	No pharmaceutical manufacturing or adherence burden
Investigational lens or miotic systems	Various	Variable	May compete through longer duration or reduced dosing frequency

VIZZ's commercial opportunity depends on whether prescribers view aceclidine as clinically differentiated from pilocarpine and whether patients accept daily unit-dose administration.

What licensing and partnership opportunities exist?

Potential transactions could involve:

• Regional commercialization rights.
• Co-development of improved preservative-free packaging.
• Manufacturing agreements with ophthalmic CDMOs.
• Supply contracts for specialty-grade excipients.
• Licensing of multidose preservative-free dispensing systems.
• Combination products pairing VIZZ with dry-eye therapies.
• International rights for jurisdictions outside the United States.

Excipient suppliers can pursue strategic agreements by offering validated alternate sources, dual-sourcing programs, and regulatory documentation rather than commodity pricing alone.

Key Takeaways

• VIZZ is an aceclidine hydrochloride ophthalmic solution for presbyopia.
• Its excipient strategy combines borate and citrate buffering with calcium, magnesium, and potassium electrolytes.
• Preservative-free delivery creates differentiation but raises packaging and sterile-manufacturing costs.
• The largest commercial opportunities are in unit-dose containers, multidose preservative-free systems, sterile excipient supply, and ophthalmic CDMO services.
• VIZZ is a small molecule, so biosimilar competition does not apply.
• Generic risk will depend on Orange Book patents, Paragraph IV challenges, formulation claims, method-of-use claims, and the ability to reproduce the reference product's sterile preservative-free presentation.
• Formulation and container-closure patents may be more commercially important than broad active-ingredient claims.

FAQs

Is VIZZ preservative-free?

VIZZ is positioned as a preservative-free ophthalmic product. That positioning supports ocular-surface tolerability claims but requires specialized sterile packaging and contamination-control systems.

Which excipient is most important in the VIZZ formulation?

No single excipient determines product performance. The commercial formulation depends on the combined buffer, electrolyte, pH, osmolality, and sterile container-closure system.

Can a generic VIZZ use different excipients?

An ANDA applicant may use different inactive ingredients if the product satisfies FDA requirements for pharmaceutical equivalence, safety, quality, and bioequivalence. Differences can create formulation, stability, or tolerability risks.

Does VIZZ face biosimilar competition?

No. Aceclidine hydrochloride is a small molecule. Follow-on products would generally use the ANDA pathway rather than the biosimilar pathway.

What is the biggest manufacturing barrier for VIZZ competitors?

The principal barrier is the integrated requirement for sterile ophthalmic solution manufacturing, preservative-free packaging, container-closure integrity, and reproducible dose delivery. A competitor must address all four areas simultaneously.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Food and Drug Administration. (n.d.). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. https://www.fda.gov/
4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
5. U.S. Food and Drug Administration. (2024). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. https://www.fda.gov/